EE200100275A - Kristalsesse olekusse konverteeritud amorfse ja/või metastabiilse kristalse piirkonnaga osakeste valmistamismeetod - Google Patents
Kristalsesse olekusse konverteeritud amorfse ja/või metastabiilse kristalse piirkonnaga osakeste valmistamismeetodInfo
- Publication number
- EE200100275A EE200100275A EEP200100275A EEP200100275A EE200100275A EE 200100275 A EE200100275 A EE 200100275A EE P200100275 A EEP200100275 A EE P200100275A EE P200100275 A EEP200100275 A EE P200100275A EE 200100275 A EE200100275 A EE 200100275A
- Authority
- EE
- Estonia
- Prior art keywords
- amorphous
- particles
- crystalline
- preparing particles
- metastable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Oxygen, Ozone, And Oxides In General (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Recrystallisation Techniques (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9804000A SE9804000D0 (sv) | 1998-11-23 | 1998-11-23 | New composition of matter |
| PCT/SE1999/002154 WO2000030614A1 (en) | 1998-11-23 | 1999-11-22 | A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200100275A true EE200100275A (et) | 2002-10-15 |
Family
ID=20413377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200100275A EE200100275A (et) | 1998-11-23 | 1999-11-22 | Kristalsesse olekusse konverteeritud amorfse ja/või metastabiilse kristalse piirkonnaga osakeste valmistamismeetod |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6475524B1 (et) |
| EP (1) | EP1133285B1 (et) |
| JP (1) | JP4447169B2 (et) |
| KR (1) | KR100697780B1 (et) |
| CN (1) | CN1198592C (et) |
| AT (1) | ATE318583T1 (et) |
| AU (1) | AU767313B2 (et) |
| BR (1) | BR9915592A (et) |
| CA (1) | CA2349633C (et) |
| CY (1) | CY1105609T1 (et) |
| CZ (1) | CZ20011778A3 (et) |
| DE (1) | DE69930158T2 (et) |
| DK (1) | DK1133285T3 (et) |
| EE (1) | EE200100275A (et) |
| ES (1) | ES2258865T3 (et) |
| HU (1) | HUP0104182A2 (et) |
| IL (2) | IL143040A0 (et) |
| IS (1) | IS5946A (et) |
| NO (1) | NO20012514L (et) |
| NZ (1) | NZ511494A (et) |
| PL (1) | PL348523A1 (et) |
| PT (1) | PT1133285E (et) |
| SE (1) | SE9804000D0 (et) |
| SK (1) | SK7032001A3 (et) |
| TR (1) | TR200101424T2 (et) |
| WO (1) | WO2000030614A1 (et) |
| ZA (1) | ZA200103946B (et) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0016002D0 (en) * | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
| DE10062712A1 (de) * | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden |
| CA2433169A1 (en) * | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Porous substances and methods for producing the same |
| ATE323549T2 (de) * | 2001-07-02 | 2006-05-15 | Micro & Nano Materials Sagl | Verfahren zur herstellung von nano- und mikro- teilchen |
| GB0126716D0 (en) * | 2001-11-07 | 2002-01-02 | Advanced Phytonics Ltd | Method for the production of particles |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| AU2005210086A1 (en) * | 2004-02-06 | 2005-08-18 | Meda Pharma Gmbh & Co. Kg | Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids |
| TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| US7968575B2 (en) | 2004-05-05 | 2011-06-28 | Renopharm Ltd. | Nitric oxide donors and uses thereof |
| US7498445B2 (en) | 2004-05-05 | 2009-03-03 | Renopharm Ltd. | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof |
| EP1753734A1 (en) | 2004-05-05 | 2007-02-21 | Renopharm Ltd. | Nitric oxide donors and uses thereof |
| US8134010B2 (en) | 2004-05-05 | 2012-03-13 | Renopharm Ltd. | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof |
| WO2006023460A2 (en) | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| JP5000095B2 (ja) * | 2005-03-11 | 2012-08-15 | 花王株式会社 | 有機結晶粒子の製造方法 |
| WO2007009164A1 (en) | 2005-07-15 | 2007-01-25 | Eiffel Technologies Limited | Method of particle formation |
| DE102006030166A1 (de) * | 2006-06-29 | 2008-01-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tempern |
| WO2009047935A1 (ja) * | 2007-10-12 | 2009-04-16 | Ono Pharmaceutical Co., Ltd. | 微粒子 |
| CN101918123B (zh) * | 2007-12-07 | 2013-12-18 | X喷雾微粒公司 | 生产微粒的方法与装置 |
| JP5138670B2 (ja) * | 2009-01-30 | 2013-02-06 | 三洋化成工業株式会社 | 樹脂粒子およびその製造方法 |
| WO2010091198A1 (en) | 2009-02-06 | 2010-08-12 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
| JP5651174B2 (ja) | 2009-07-15 | 2015-01-07 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ビフェニル化合物の結晶性遊離塩基形 |
| WO2011109635A1 (en) | 2010-03-03 | 2011-09-09 | Neonc Technologies Inc. | Pharmaceutical compositions comprising monoterpenes |
| US20160038600A1 (en) | 2012-08-03 | 2016-02-11 | Neonc Technologies Inc. | Pharmaceutical compositions comprising poh derivatives |
| CN110464718A (zh) | 2010-08-27 | 2019-11-19 | 尼昂克技术公司 | 包含poh衍生物的药物组合物 |
| DK2651864T3 (en) | 2010-12-17 | 2016-09-05 | Neonc Tech Inc | Methods and devices for use of isoperillylalkohol |
| PL2968312T3 (pl) | 2013-03-15 | 2018-08-31 | Verona Pharma Plc | Kombinacja leków |
| GB201402556D0 (en) | 2014-02-13 | 2014-04-02 | Crystec Ltd | Improvements relating to inhalable particles |
| US10864213B2 (en) | 2014-05-12 | 2020-12-15 | Verona Pharma Plc | Treatment |
| CN107613768B (zh) | 2015-02-12 | 2020-10-20 | NeOnc技术股份有限公司 | 包含紫苏醇衍生物的药物组合物 |
| JP7144411B2 (ja) | 2016-11-30 | 2022-09-29 | ネオンク テクノロジーズ インク． | ペリリルアルコール－３－ブロモピルベート複合体及びがんの治療方法 |
| WO2019157195A1 (en) | 2018-02-08 | 2019-08-15 | Neonc Technologies, Inc | Methods of permeabilizing the blood brain barrier |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9101090D0 (sv) | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
| SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| US5639441A (en) * | 1992-03-06 | 1997-06-17 | Board Of Regents Of University Of Colorado | Methods for fine particle formation |
| GB9313642D0 (en) * | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
| GB9413202D0 (en) * | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
| ATE212545T1 (de) | 1995-03-28 | 2002-02-15 | Fidia Advanced Biopolymers Srl | Nanosphären mit einem biokompatiblen polysaccharid |
| DK1393721T3 (da) | 1997-03-20 | 2009-03-30 | Schering Corp | Doseringsform af pulveragglomerater |
-
1998
- 1998-11-23 SE SE9804000A patent/SE9804000D0/xx unknown
-
1999
- 1999-11-22 DE DE69930158T patent/DE69930158T2/de not_active Expired - Lifetime
- 1999-11-22 SK SK703-2001A patent/SK7032001A3/sk unknown
- 1999-11-22 WO PCT/SE1999/002154 patent/WO2000030614A1/en active IP Right Grant
- 1999-11-22 CZ CZ20011778A patent/CZ20011778A3/cs unknown
- 1999-11-22 CA CA002349633A patent/CA2349633C/en not_active Expired - Fee Related
- 1999-11-22 AT AT99963731T patent/ATE318583T1/de not_active IP Right Cessation
- 1999-11-22 TR TR2001/01424T patent/TR200101424T2/xx unknown
- 1999-11-22 EP EP99963731A patent/EP1133285B1/en not_active Expired - Lifetime
- 1999-11-22 ES ES99963731T patent/ES2258865T3/es not_active Expired - Lifetime
- 1999-11-22 CN CNB998136093A patent/CN1198592C/zh not_active Expired - Fee Related
- 1999-11-22 DK DK99963731T patent/DK1133285T3/da active
- 1999-11-22 US US09/486,675 patent/US6475524B1/en not_active Expired - Fee Related
- 1999-11-22 KR KR1020017006444A patent/KR100697780B1/ko not_active IP Right Cessation
- 1999-11-22 JP JP2000583498A patent/JP4447169B2/ja not_active Expired - Fee Related
- 1999-11-22 AU AU20104/00A patent/AU767313B2/en not_active Ceased
- 1999-11-22 PL PL99348523A patent/PL348523A1/xx not_active Application Discontinuation
- 1999-11-22 EE EEP200100275A patent/EE200100275A/et unknown
- 1999-11-22 HU HU0104182A patent/HUP0104182A2/hu unknown
- 1999-11-22 BR BR9915592-3A patent/BR9915592A/pt not_active Application Discontinuation
- 1999-11-22 IL IL14304099A patent/IL143040A0/xx unknown
- 1999-11-22 PT PT99963731T patent/PT1133285E/pt unknown
- 1999-11-22 NZ NZ511494A patent/NZ511494A/en not_active IP Right Cessation
-
2001
- 2001-05-08 IL IL143040A patent/IL143040A/en not_active IP Right Cessation
- 2001-05-15 ZA ZA200103946A patent/ZA200103946B/xx unknown
- 2001-05-18 IS IS5946A patent/IS5946A/is unknown
- 2001-05-22 NO NO20012514A patent/NO20012514L/no not_active Application Discontinuation
-
2006
- 2006-05-17 CY CY20061100642T patent/CY1105609T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200100275A (et) | Kristalsesse olekusse konverteeritud amorfse ja/või metastabiilse kristalse piirkonnaga osakeste valmistamismeetod | |
| PT1133284E (pt) | Um processo para a preparacao de particulas cristalinas | |
| CA2339221A1 (en) | Extracts of feverfew (tanacetum parthenium) against inflammatory disorders | |
| NO20025450D0 (no) | Ny farmasöytisk sammensetning | |
| BR0214967A (pt) | Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente | |
| UA48946C2 (uk) | Арилалкілдіазинони, спосіб їх одержання (варіанти), фармацевтичний склад, спосіб його одержання та спосіб лікування | |
| BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
| FI934983A (fi) | Kinuklidinderivat foer behandling av inflammatoriska och gastrointestinala sjukdomar | |
| HUP0202461A2 (hu) | Gyógyászati készítmények és azok agyvérzés, diabetes és/vagy elzáródásos szívbénulás megelőzésében történő alkalmazása | |
| BR9909958A (pt) | Formulação farmacêutica, respectivos processo de preparação e uso e método de tratamento ou prevenção de distúrbios ósseos | |
| ATE234089T1 (de) | Zubereitungen enthaltend sclareol und sclareolide zur behandlung mikrobieller infektionen | |
| WO2001001974A3 (en) | Naaladase inhibitors in anxiety and memory disorders | |
| NO962752L (no) | Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose | |
| NO903384L (no) | Fremgangsmaate for fremstilling av 4-(n-substituert amino)-2-butynyl-1-urinstoffer og -tiourinstoffer og derivater derav. | |
| ATE309811T1 (de) | Analgetikum aus schlangengift | |
| NO982863L (no) | Nye forbindelser med analgetisk effekt | |
| CN1069196C (zh) | 利福平在制备治疗淋病用的药物中的应用 | |
| BR0316123A (pt) | Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico | |
| HUP0300043A2 (en) | Method and composition for the treatment of pain | |
| NO951865L (no) | Quinuclidin-derivat som substans-P antagonist | |
| RU99125714A (ru) | Способ остеотомии |